. * * window.aa needs to exist and be usable by ANY module's script, * however early it runs - main-nav's script, for one, runs near * the top of

91̽»¨

, well before the real search-insights.js * so the download * begins as early as before. Repeat calls share the same downloads, a * failed load is retried on the next call, and the versions / SRI * hashes live only here. * * Algolia Insights is unaffected: window.aa above is still created in * on every page and queues events until search-insights loads. * * window.loadAlgoliaLibs({ priority: 'high' }) (Oct 2026): used by the * /search page, where the first results wait on these libraries. Chrome * gives async scripts low priority, behind images and fonts; this asks * for high instead (fetchpriority). Only the first call for a library * sets its priority - later calls share that download. */ (function (win, doc) { var LIBS = [ { ready: function () { return !!win['algoliasearch/lite']; }, src: 'https://cdn.jsdelivr.net/npm/algoliasearch@5.52.1/dist/lite/builds/browser.umd.js', integrity: 'sha256-I2oYUIvhx1g6l4lTP+yoERbzLIHKzw4AKaBRQPwIeDY=' }, { ready: function () { return !!win.instantsearch; }, src: 'https://cdn.jsdelivr.net/npm/instantsearch.js@4.98.0/dist/instantsearch.production.min.js', integrity: 'sha256-ngmqZk4WBxUw257aMYZayyNBd983INngagv0jI6Ecfs=' } ]; function loadOne(lib, options) { if (lib.ready()) return Promise.resolve(); // One download per library, shared by every caller; reset on // failure so the next call retries just the library that failed. if (lib.pending) return lib.pending; lib.pending = new Promise(function (resolve, reject) { var script = doc.createElement('script'); script.src = lib.src; script.integrity = lib.integrity; script.crossOrigin = 'anonymous'; script.async = true; if (options && options.priority === 'high') script.setAttribute('fetchpriority', 'high'); script.onload = function () { lib.ready() ? resolve() : reject(new Error('Loaded but not available: ' + lib.src)); }; script.onerror = function () { script.remove(); reject(new Error('Could not load ' + lib.src)); }; doc.head.appendChild(script); }); lib.pending.catch(function () { lib.pending = null; }); return lib.pending; } win.loadAlgoliaLibs = function (options) { return Promise.all(LIBS.map(function (lib) { return loadOne(lib, options); })); }; })(window, document); . */ window.hsConversationsSettings = window.hsConversationsSettings || {}; window.hsConversationsSettings.loadImmediately = false; (function (win) { var EVENTS = ['pointerdown', 'keydown', 'touchstart', 'scroll', 'mousemove', 'wheel']; var done = false; /* 19 Oct 2026 - chat widget layout shift (field CLS). Phones fail Core Web Vitals on CLS (p75 ~0.2 site-wide in CrUX for months). Biggest cause found: HubSpot's chat container is fixed to the bottom-right corner and changes size - 100x96 launcher to 282x253 when the welcome message pops up (~5 s after load), and to full screen when a visitor opens the chat. Its top-left corner moves, so Chrome scores it as a layout shift: 0.088 per page view at 360x640 (0.044 at 412x850), on every page. Taps happen inside the chat iframe, so the parent page never sees the input and the open/close shifts count too. Fix: whenever the container's size changes it is made transparent for 400 ms (Chrome doesn't score shifts of invisible elements), then shown again at its new size. Tested on live io1001 at 360x640 in a cookie-less frame: the 0.088 shift no longer appears. The chat itself is unchanged - it just appears 0.4 s later at each resize. Relies on HubSpot's container id; if that changes this does nothing (no error). */ function cloakChatResizes() { var ID = 'hubspot-messages-iframe-container'; function watch(c) { if (c.getAttribute('data-bb-cloak')) return; c.setAttribute('data-bb-cloak', '1'); var last = c.offsetWidth + 'x' + c.offsetHeight, timer = null; new MutationObserver(function () { var size = c.offsetWidth + 'x' + c.offsetHeight; if (size === last) return; last = size; c.style.setProperty('opacity', '0', 'important'); clearTimeout(timer); timer = setTimeout(function () { c.style.removeProperty('opacity'); }, 400); }).observe(c, { attributes: true, attributeFilter: ['style', 'class'], subtree: true, childList: true }); } var found = document.getElementById(ID); if (found) { watch(found); return; } if (!document.body || !('MutationObserver' in win)) return; var mo = new MutationObserver(function () { var c = document.getElementById(ID); if (c) { mo.disconnect(); watch(c); } }); mo.observe(document.body, { childList: true }); setTimeout(function () { mo.disconnect(); }, 30000); } function loadWidget() { var api = win.HubSpotConversations; if (api && api.widget && api.widget.status && api.widget.status().loaded) return; try { cloakChatResizes(); } catch (e) {} if (api && api.widget) api.widget.load(); } function onFirstInteraction() { if (done) return; done = true; EVENTS.forEach(function (type) { win.removeEventListener(type, onFirstInteraction, { passive: true }); }); var start = function () { if (win.HubSpotConversations) loadWidget(); else (win.hsConversationsOnReady = win.hsConversationsOnReady || []).push(loadWidget); }; if ('requestIdleCallback' in win) win.requestIdleCallback(start, { timeout: 1500 }); else setTimeout(start, 200); } EVENTS.forEach(function (type) { win.addEventListener(type, onFirstInteraction, { passive: true }); }); })(window);

91̽»¨

Skip to main content
Producing 3D Neuronal Microtissues for Preclinical Drug Screening using ioGlutamatergic Neurons
application note

Producing 3D Neuronal Microtissues for Preclinical Drug Screening using ioGlutamatergic Neurons

In this application note, ioGlutamatergic neurons and iPSC-derived astrocytes are used in 3D microtissues, created with the RASTRUMâ„¢ 3D cell culture platform. The platform supports both 96- and 384-well formats and mimics key CNS features like neurite outgrowths. This offers a powerful model system for medium- to high-throughput drug screening and more productive preclinical drug development.
Producing 3D Neuronal Microtissues for Preclinical Drug Screening using ioGlutamatergic Neurons
In this application note, ioGlutamatergic neurons and iPSC-derived astrocytes are used in 3D microtissues, created with the RASTRUMâ„¢ 3D cell culture platform. The platform supports both 96- and 384-well formats and mimics key CNS features like neurite outgrowths. This offers a powerful model system for medium- to high-throughput drug screening and more productive preclinical drug development.

3D cell culture models using human induced pluripotent stem cells (iPSCs) have emerged as a promising, human relevant model system for the study of central nervous system (CNS) disorders. Unlike two-dimensional cell culture, 3D cultures achieve physiological relevance by culturing cells in a 3D environment with many of the factors that influence cell behavior in vivo. However, the complexity of iPSC differentiation has hindered adoption of these models for high-throughput drug screening, leaving researchers to rely on 2D models with poor predictive validity. ioCellsâ„¢ from 91̽»¨, generated through opti-oxâ„¢ technology, provide a solution by using deterministic cell programming to consistently generate mature human neuronal cells at scale.

Herein, we delve into a recent study using the RASTRUMâ„¢ 3D cell culture platform from Inventia Life Science to generate neuronal microtissues composed of ioGlutamatergic neurons and iPSC-derived astrocytes. The microtissues are formed within a composite hydrogel scaffold mimicking key CNS microenvironmental features. These 3D co-cultures, formed in both 96- and 384-well plate formats, exhibited mature neuronal phenotypes with characteristic neurite outgrowths. Such a model offers a robust and scalable system for medium- to high-throughput drug discovery assays, thereby enabling more productive preclinical drug development. 

In this application note, you will discover: 

  • How ioCells enable 3D co-culture of mature human neurons
  • How neuronal microtissues can be built en masse using ioCells and the RASTRUM 3D cell culture platform
  • Characteristics of human iPSC-derived neuronal microtissues that may be of value in medium- to high-throughput drug screening.
V1
2024
91̽»¨
Inventia

Related pages

91̽»¨ Learn about our range of human iPSC-derived cells for research and drug discovery
Our platform Discover the cell coding platform behind our cells
Contact us Talk to us to learn more about our team and products